SOLV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.96B

-5.45%

1.493

+5.92%

1.95B

-6.02%

1.481

+10.53%

2.02B

-6.38%

1.634

-3.32%

Estimates Revision

The market is revising Upward the revenue expectations for Solventum Corporation (SOLV) for FY2025, with the revenue forecasts being adjusted by 0.93% over the past three months. During the same period, the stock price has changed by 19.97%.

Revenue Estimates for FY2025

Revise Upward

+0.93%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.07%

In Past 3 Month

Stock Price

Go Up

+19.97%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is 87.86 USD with a low forecast of 79.00 USD and a high forecast of 103.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

79.00

Averages

87.86

High

103.00

Current: 0.000

Low

79.00

Averages

87.86

High

103.00

BTIG

Neutral -> Buy

upgrade

$100

2025-12-02

Reason

BTIG

Price Target

$100

2025-12-02

upgrade

Neutral -> Buy

Reason

BTIG upgraded Solventum to Buy from Neutral with a $100 price target.

BTIG

Ryan Zimmerman

Neutral -> Buy

upgrade

$100

2025-12-02

Reason

BTIG

Ryan Zimmerman

Price Target

$100

2025-12-02

upgrade

Neutral -> Buy

Reason

BTIG analyst Ryan Zimmerman upgraded Solventum to Buy from Neutral with a $100 price target. The firm believes the company will find its "footing" in 2026. The company's divestiture of its purification and filtration business helped reduce its debt, says BTIG, which cites Solventum's execution against guidance and reduced buy-side expectations for the upgrade. It finds the stock's setup "compelling" at current valuation levels.

UBS

Neutral

maintain

$77 -> $79

2025-11-10

Reason

UBS

Price Target

$77 -> $79

2025-11-10

maintain

Neutral

Reason

UBS raised the firm's price target on Solventum to $79 from $77 and keeps a Neutral rating on the shares. Solventum delivered strong Q3 results and proactively addressed 2026 margin concerns with a new $500M long-term cost savings plan, the analyst tells investors in a research note. While initial benefits may be modest, projected 2026 adjusted net income and EPS growth have been raised to 6%, supported by better-than-expected revenue trends, UBS says.

Piper Sandler

Jason Bednar

Overweight

maintain

$94 -> $98

2025-11-07

Reason

Piper Sandler

Jason Bednar

Price Target

$94 -> $98

2025-11-07

maintain

Overweight

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on Solventum to $98 from $94 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that included revenue of $2,096M/+2.7% organic and EPS of $1.50, another quarter of outperformance vs. consensus expectations and living up to the beat/raise call it previewed. This is the seventh consecutive quarter in which management has delivered upside vs. Street, and it's also the fourth guidance raise during that time, Piper adds.

UBS

Kevin Caliendo

Neutral

initiated

$77

2025-10-01

Reason

UBS

Kevin Caliendo

Price Target

$77

2025-10-01

initiated

Neutral

Reason

UBS analyst Kevin Caliendo initiated coverage of Solventum with a Neutral rating and $77 price target. The firm sees the company's growth moderating in the near term due to industry SKU rationalization and tougher compares. It views the shares as appropriately valued given Solventum's current portfolio setup.

Wells Fargo

Equal Weight

maintain

$79 -> $82

2025-09-14

Reason

Wells Fargo

Price Target

$79 -> $82

2025-09-14

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Solventum to $82 from $79 and keeps an Equal Weight rating on the shares. The firm is updating its price target on the stock to reflect the sale of the company's P&F business, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Solventum Corp (SOLV.N) is 12.66, compared to its 5-year average forward P/E of 12.26. For a more detailed relative valuation and DCF analysis to assess Solventum Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.26

Current PE

12.66

Overvalued PE

13.43

Undervalued PE

11.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.22

Current EV/EBITDA

9.26

Overvalued EV/EBITDA

10.44

Undervalued EV/EBITDA

8.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.47

Current PS

1.72

Overvalued PS

1.64

Undervalued PS

1.30

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SOLV News & Events

Events Timeline

No data

News

8.5

2025-12-23PRnewswire

Solventum Acquires Acera for $725 Million, Enhancing Wound Care Portfolio

8.5

2025-12-23Newsfilter

Solventum Acquires Acera for $725 Million, Expanding MedSurg Portfolio

4.5

2025-12-22SeekingAlpha

Solventum Leads the Pack in Healthcare Supplies Stocks This Year

People Also Watch

Frequently Asked Questions

What is Solventum Corp (SOLV) stock price today?

The current price of SOLV is 86.14 USD — it has increased 0.43 % in the last trading day.

What is Solventum Corp (SOLV)'s business?

Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.

What is the price predicton of SOLV Stock?

What is Solventum Corp (SOLV)'s revenue for the last quarter?

Solventum Corp revenue for the last quarter amounts to 2.10B USD, increased 0.67 % YoY.

What is Solventum Corp (SOLV)'s earnings per share (EPS) for the last quarter?

Solventum Corp. EPS for the last quarter amounts to 7.22 USD, increased 931.43 % YoY.

What changes have occurred in the market's expectations for Solventum Corp (SOLV)'s fundamentals?

How many employees does Solventum Corp (SOLV). have?

Solventum Corp (SOLV) has 22000 emplpoyees as of January 09 2026.

What is Solventum Corp (SOLV) market cap?

Today SOLV has the market capitalization of 14.88B USD.